Results 201 to 210 of about 144,202 (264)

Nonparametric maximum likelihood estimation of the survival function using current lifetime data

Canadian Journal of Statistics, EarlyView.
Abstract An issue when estimating the failure time survival function is how to set up a prevalent cohort study infrastructure to follow subjects after enrollment. This problem can be circumvented through the well‐known Grenander density estimator using current lifetime observations only.
James H. McVittie, Masoud Asgharian
wiley   +1 more source

Time of week intensity estimation from partly interval censored data with applications to police patrol planning. [PDF]

J Appl Stat
Tian J, Porter MD.
europepmc   +1 more source

Group lasso priors for Bayesian accelerated failure time models with left-truncated and interval-censored data. [PDF]

Stat Methods Med Res
Reeder HT, Haneuse S, Lee KH.
europepmc   +1 more source

Exploring Healthcare Continuity in Pediatric‐Onset Multiple Sclerosis in the United States

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Objective Little is known about shifting from pediatric to adult‐focused multiple sclerosis (MS) care. This study aims to explore transition of care and follow‐up in the US pediatric‐onset MS (POMS) population. Methods Surveys were distributed to 10 sites in the US Network of Pediatric MS Centers (US NPMSC) about transition‐of‐care practices ...
Aaron W. Abrams, Michael Waltz, Jonathan Race, T. Charles Casper, Claudia Gambrah‐Lyles, Kimberly O'Neill, Akash Virupakshaiah, Kristen S. Fisher, Melissa A. Wright, Kelsey E. Poisson, Eva‐Chava M. Bernfeld, Gregory Aaen, Leslie A. Benson, Tanuja Chitnis, Carla Francisco, Grace Y. Gombolay, Mark P. Gorman, Jennifer S. Graves, Lauren Krupp, Timothy E. Lotze, Soe Mar, Jayne Ness, Mary Rensel, Moses Rodriguez, Teri Schreiner, Nikita Shukla, Jan‐Mendelt Tillema, Bianca Weinstock‐Guttman, Yolanda Wheeler, Emmanuelle Waubant, John Rose, US Network of Pediatric MS Centers   +31 more
wiley   +1 more source

Statistical analysis of the k/n(G) system with dependent competing failure components influenced by Gumbel-Hougarrd Copula and progressively hybrid censored data. [PDF]

Heliyon
Shi Y, Yan Z, Peng X.
europepmc   +1 more source

Association of Urinary pH With Overall Survival in Patients With Stage IV Cancer: A Single‐Center Retrospective Cohort Study

Cancer Nexus, EarlyView.
ABSTRACT Objective This single‐center retrospective cohort study evaluated whether, among patients with stage IV cancer who participated in a pragmatic “alkalization therapy”—defined as a low potential renal acid load diet plus oral sodium bicarbonate and/or potassium/sodium citrate—urinary pH was associated with long‐term survival.
Shion Kachi, Kazuyuki Suzuki, Reo Hamaguchi, Ryoko Narui, Hiromasa Morikawa, Hiromi Wada   +5 more
wiley   +1 more source

Bayesian transformation model for spatial partly interval-censored data. [PDF]

J Appl Stat
Qiu M, Hu T.
europepmc   +1 more source

Genomic Insights Into Risperidone Treatment Outcomes in Children and Adolescents: Experience From a Psychiatric Hospital Serving Rural Youth

Clinical Pharmacology &Therapeutics, EarlyView.
Risperidone is a commonly used antipsychotic for treating psychiatric illness in children and adolescents. There is a large variability in risperidone response and discontinuation rates remain high. Pharmacogenomics offers the opportunity to improve risperidone outcomes, yet studies in pediatric populations are limited.
Jack W. Staples, Shayna R. Killam, Karen E. Brown, Rachel Dalton, Elizabeth Sather, Qiang Chen, Joshua Loveland, Corbin Schwanke, Abdallah F. Elias, Kristin L. Bigos, Erica L. Woodahl   +10 more
wiley   +1 more source

PICBayes: Bayesian proportional hazards models for partly interval-censored data. [PDF]

Commun Stat Simul Comput
Pan C, Cai B.
europepmc   +1 more source

Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib

Clinical Pharmacology &Therapeutics, EarlyView.
Repurposing drugs whose clinical safety has been established offers a valuable approach to reduce the cost and time associated with the development of new drugs for malaria. Here, we investigate the potential to repurpose the anticancer kinase inhibitor berzosertib for the treatment of malaria, by assessing whether a predicted efficacious human dose ...
Devasha Redhi, Mwila Mulubwa, Mmakwena M. Mmonwa, Mathew Njoroge, Liezl Krugmann, Kelly Chibale   +5 more
wiley   +1 more source